Ipsen announces results of phase III study of somatuline in patients with neuroendocrine tumors

IpsenAug 31 2013

“A randomized, double-blind, placebo-Controlled study of Lanreotide Antiproliferative Response in patients with gastroenteropancreatic NeuroEndocrine Tumors (CLARINET)”

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the detailed results of phase III CLARINET study assessing the effect of Somatuline^® Autogel^® 120 mg in patients with gastrointestinal and pancreatic neuroendocrine tumors ("GEP-NETs")¹ will be disclosed for the first time on September 28, 2013 at the European Cancer Congress 2013 (Sept. 27 - Oct. 1, 2013) in Amsterdam.

CLARINET results will be presented by Prof. Philippe Ruszniewski, Head Gastroenterology-Pancreatology Dept, Beaujon Hospital, Clichy, and Paris Diderot University (France), one of the investigators of the study, to the medical community on Saturday 28 September at 3:35pm (hall 7.1) during Presidential Session I (1:45-3:55 pm). A press conference will be held at 4:30pm (Emerald room), in presence notably of Marc de Garidel, Chairman and CEO of Ipsen and of Prof. Philippe Ruszniewski.

The abstract number is LBA 3, "A randomized, double-blind, placebo-Controlled study of Lanreotide Antiproliferative Response in patients with gastroenteropancreatic NeuroEndocrine Tumors (CLARINET)".